A Phase 1, two-treatment, fixed-sequence study with an open-label design was conducted to assess the impact of ARA on the PK profile of Sparsentan in 20 healthy adult male and female participants.
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Sparsentan (Primary) ; Esomeprazole
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Focal segmental glomerulosclerosis; Hereditary nephritis; IgA nephropathy; Vasculitis
- Focus Pharmacokinetics
- 21 Jan 2025 New trial record